Navigating the Pharma Data Revolution with AstraZeneca
from Cloud Advantages to RWE Insights
How to accelerate research to support the generation of improved patient outcomes
Join our exclusive webinar with NTT DATA and AstraZeneca Japan healthcare technology executives for an expert discussion on RWE in commercial and medical fields, and the challenges — and benefits — of implementing effective patient and clinical big data analytics.
COVID-19 changed the world. The response to it transformed healthcare.
The pandemic put drug discovery and clinical trials in the public spotlight more than ever before. Real-world evidence (RWE) and clinical data became priceless commodities in the research and development of vaccines and medications to combat the global threat of coronavirus.
More recently, global regulators have incentivized real-world data (RWD) in clinical trials to improve healthcare and patient outcomes, from research directions and pharmaceutical efficacy to medication adherence and medical cost. At the same time, changing disease profiles and patient expectations have made secure, personalized digital healthcare experiences essential.
In a post-pandemic world, how can we effectively scale RWD to size the market, drive product strategy and create greater value for patients and medical professionals?
Pharmaceutical, medical product and life sciences companies can achieve a distinct competitive advantage by integrating RWD into R&D to shorten the discovery cycle, improve population health outcomes and customize patient care. With the rise of Generative AI, we see the potential to automate and curate, accelerating research processes and insight generation.
However, processing large volumes of unstructured RWD with surgical precision presents technical and organizational challenges in an endlessly growing data ecosystem.
Streamlining, harmonizing and analyzing data from multiple sources increases the risk of inaccurate or unintentionally biased information. Compared to legacy systems, collecting patient data in real-time from remote channels such as wearables puts greater pressure on consumer privacy and protection.
Join Phil Rust (Lead Enterprise Architect, Healthcare, NTT DATA UK&I) and Harsh Gandhi (Chief Information and Digital Officer AstraZeneca K.K.) on an exclusive webinar to learn how cutting-edge technologies can address these challenges and deliver better business and patient outcomes.
From improved cohort selection and data security to optimal sales and marketing efforts, the expert session will tackle the key technical, operational and strategic benefits of RWE implementation and process optimization, the role of system integrators, and future trends for both technology and industry.
Harsh Gandhi
Chief Information & Digital Officer AstraZeneca K.K.
Harsh Gandhi has 20+ years of global experience in transforming health care delivery through next generation customer engagement models and optimising patient pathways by leveraging digital and data. In his current role at AstraZeneca, he is responsible for defining digital & data strategy, exploring new technology led business models, uplifting digital talent and delivering scalable and cost-effective platforms to improve patient's life and contribute to Japanese society and health care system in sustainable way. Harsh is active in shaping and mentoring new start-ups in health care & technology sector in Asia and Africa as part of Stanford SEED.
Phil Rust
Lead Enterprise Architect, Healthcare
NTT DATA UK&I
Phil is an accomplished leader in digital transformation, boasting a rich career spanning several decades in developing impactful data and technology solutions. His expertise lies in the healthcare sector, focusing on technology integration and the utilization of real-world data within complex environments. Phil's commitment to revolutionizing healthcare through technologically driven insights, underpinned by his vast subject matter expertise, marks him as a distinguished figure in his field.
